Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Trauma Injury Clinical Trial

— MATIC-2  

Official title:

Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06070350
• Other study ID #: MATIC-002
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 1, 2024
• Est. completion date: September 1, 2028

Study information

• Verified date: October 2023
• Source: University of Pittsburgh
• Contact: Jane Luce
• Phone: 412-383-7853
• Email: jane.luce[@]pitt.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion.

The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.

Description:

The MATIC-2 trial is a Bayesian, randomized, multicenter, adaptive platform phase III trial. The trial will include injured children with hemorrhagic shock anticipated to require massive blood transfusion, who will be randomized to receive either LTOWB or CT and Tranexamic Acid or placebo.

The study investigators hypothesize that the use of LTOWB is non-inferior and/or superior for 24-hour mortality and that LTOWB does not increase the risk of adverse events or outcomes, such as thrombotic events, compared to CT.

The investigators also hypothesize that the use of TXA is superior for 24-hour mortality and does not increase the risk of adverse events or outcomes, such as thrombotic events, compared to placebo.

Objectives:

The primary objectives are to:

1. Determine the effectiveness of LTOWB to reduce all-cause 24-hour mortality compared to CT in children with traumatic life-threatening hemorrhage.

2. Determine the effectiveness of TXA to reduce all-cause 24-hour mortality compared to placebo in children with traumatic life-threatening hemorrhage.

Secondary objectives are to determine the effectiveness and safety of LTOWB and TXA to improve secondary and exploratory outcomes (or endpoints) in children with traumatic life-threatening hemorrhage.

Safety objectives are to determine the effect of LTOWB and TXA on safety related outcomes/endpoints. The safety outcomes include:

1. Acute kidney injury

2. Acute respiratory distress syndrome

3. Sepsis

4. Thromboembolism: arterial and venous

5. Markers of hemolysis

6. Alloimmunization in Rh negative female recipients of Rh+ LTOWB

7. Transfusion-related adverse events 8 Serious Adverse Events (SAEs)

Mechanistic Objectives are to:

1. Define trauma induced coagulopathy (TIC) according to measures of shock, hemostasis, and endothelial and immune function.

2. To determine if measures of shock, endothelial, immune, and hemostasis function upon admission (TIC endotype) predicts which hemostatic resuscitation therapies or combinations of therapies (LTOWB, CT, LTOWB + TXA, CT+TXA) for each study group improves outcomes without increasing the risk of adverse events.

3. To determine the mechanisms of how hemostatic resuscitation therapies or combinations of therapies (LTOWB, CT, LTOWB + TXA, CT+TXA) improve TIC endotypes and outcomes.

Pharmacokinetic objectives are to evaluate the PK and PD properties of TXA in a population of children with life-threatening traumatic bleeding.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: September 1, 2028
• Est. primary completion date: March 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria:

1. Children, defined as less than 18 years of age with traumatic injury

2. MTP activation for confirmed or suspected active life-threatening traumatic bleeding

AND

Confirmed or suspected active life-threatening traumatic bleeding with at least 2 of 3 of the following criteria:

1. Hypotension for age (< 5% tile)

2. Tachycardia for age (>95th % tile)

3. Traumatic injury with exam findings consistent with severe bleeding (e.g., penetrating injury, hemothorax, distended abdomen with bruising, amputation of limb).

Exclusion Criteria:

1. Unknown time of injury

2. Greater than 3 hours since time of injury

3. History of seizure after the injury event

4. Known allergy or hypersensitivity reaction to TXA

5. Comatose (Glasgow Coma Score of 3) with fixed and dilated pupils suggesting nonsurvivable brain injury

6. MTP activated but no blood products given

7. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)

8. Patients who are obviously pregnant on clinical examination

9. Known prisoners as defined in protocol

10. Known ward of the state

11. Isolated hanging, drowning or burns

12. Previous enrollment in MATIC-2

13. Prior study opt-out with bracelet

Related Conditions & MeSH terms

• Hemorrhagic Shock
• Shock, Hemorrhagic
• Trauma Injury

Intervention

Biological:
• Low Titer Group O Whole Blood (LTOWB)
LTOWB is whole blood from group O donors with low titer (<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.

Drug:
• Placebo
Placebo will be made by the research pharmacy at each of the clinical sites
• Tranexamic Acid (TXA)
TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure.

Biological:
• Component Therapy (CT)
Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Philip Spinella	Biomedical Advanced Research and Development Authority

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24 hours all cause mortality		24 hours
Secondary	6-hour, 72-hour and 28-day survival	Cumulative survival over time through 28 days post-enrollment: includes 6-hour, 72-hour and 28-day survival.	6, 72 hours and 28 days
Secondary	24 hours total blood product transfusion volumes	Total blood product transfusion in 24 hours after enrollment.	24 hours